Affimed Dirección

Dirección controles de criterios 3/4

El CEO de Affimed's es Andreas Harstrick , nombrado en Jan 2024, tiene una permanencia de menos de un año. compensación anual total es €1.14M, compuesta por 34% salario y 66% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.5% de las acciones de la empresa, por valor de €380.13K. La antigüedad media del equipo directivo y de la junta directiva es de 6.6 años y 8.8 años, respectivamente.

Información clave

Andreas Harstrick

Chief Executive Officer (CEO)

€1.1m

Compensación total

Porcentaje del salario del CEO	34.0%
Permanencia del CEO	less than a year
Participación del CEO	0.5%
Permanencia media de la dirección	6.7yrs
Promedio de permanencia en la Junta Directiva	8.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Andreas Harstrick en comparación con los beneficios de Affimed?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	€1m	€388k	-€106m
Sep 30 2023	n/a	n/a	-€119m
Jun 30 2023	n/a	n/a	-€111m
Mar 31 2023	n/a	n/a	-€101m
Dec 31 2022	€1m	€374k	-€86m
Sep 30 2022	n/a	n/a	-€76m
Jun 30 2022	n/a	n/a	-€76m
Mar 31 2022	n/a	n/a	-€76m
Dec 31 2021	€1m	€368k	-€58m
Sep 30 2021	n/a	n/a	-€49m
Jun 30 2021	n/a	n/a	-€38m
Mar 31 2021	n/a	n/a	-€32m
Dec 31 2020	€567k	€256k	-€41m

Compensación vs. Mercado: La compensación total de Andreas($USD1.22M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD406.04K).

Compensación vs. Ingresos: La compensación de Andreas ha sido consistente con los resultados de la empresa en el último año.

CEO

Andreas Harstrick (62 yo)

less than a year

Permanencia

€1,140,000

Compensación

Dr. Andreas Harstrick M.D., has been Chief Medical Officer of Affimed N.V. since March 1, 2020 and serves as its Member of Management Board and serves as its Interim Chief Executive Officer since January 1...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Andreas Harstrick	Interim CEO	less than a year	€1.14m	0.50% € 380.4k
Wolfgang Fischer	MD, COO & Member of Management Board	6.7yrs	€1.26m	0.96% € 728.1k
Denise Mueller	Chief Business Officer & Member of Management Board	2.9yrs	€1.17m	0.59% € 449.7k
Melvyn Little	Founder & Consultant	24.3yrs	sin datos	sin datos
Michael Wolf	Head of Finance & Administration	9.3yrs	sin datos	sin datos
Alexander Fudukidis	Head of Investor Relations & Director of Investor Relations	no data	sin datos	sin datos
Mary Sandin	Vice President of Marketing & Communications	no data	sin datos	sin datos

6.7yrs

Permanencia media

57.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de A28A es experimentado (6.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ulrich Grau	Independent Member of Supervisory Board	8.8yrs	€85.00k	0.13% € 100.1k
Miroslav Ravic	Member of Scientific Advisory Board	no data	sin datos	sin datos
Thomas Hecht	Independent Chairman of Supervisory Board	17.3yrs	€162.00k	0.25% € 192.8k
Uta Kemmerich-Keil	Independent Member of Supervisory Board	2.9yrs	€139.00k	0.072% € 55.0k
Susanne Becker	Member of Scientific Advisory Board	no data	sin datos	sin datos
Andreas Engert	Member of Scientific Advisory Board	no data	sin datos	sin datos
Max Topp	Member of Scientific Advisory Board	no data	sin datos	sin datos
Christian Hucke	Member of Scientific Advisory Board	no data	sin datos	sin datos
Anton Hagenbeek	Member of Scientific Advisory Board	no data	sin datos	sin datos
Franck Morschhauser	Member of Scientific Advisory Board	no data	sin datos	sin datos
Ulrike Köhl	Member of Scientific Advisory Board	no data	sin datos	sin datos
Stephen Ansell	Member of Scientific Advisory Board	8.9yrs	sin datos	sin datos

8.9yrs

Permanencia media

73yo

Promedio de edad

Junta con experiencia: La junta directiva de A28A se considera experimentada (8.8 años de antigüedad promedio).

Affimed Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Affimed N.V. Announces CEO Changes

Affimed N.V. Announces Executive Changes

Affimed Announces Addition of Constanze Ulmer-Eilfort to Its Supervisory Board

Affimed N.V., Annual General Meeting, Jun 21, 2023

Affimed N.V. Establishes Scientific Advisory Board

Recent updates

Affimed N.V. to Report Fiscal Year 2023 Results on Mar 28, 2024

Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer

Affimed N.V. Announces CEO Changes

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic Nk in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (Bv) and Checkpoint Inhibitors (Cpis)

Affimed N.V. Announces Executive Changes

Affimed N.V. to Report Q3, 2023 Results on Nov 14, 2023

Affimed N.V. Presents Preclinical Data Showing That Addition of an Innate Cell Engager to Nk and Car-Nk Cells

Affimed N.V. Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

Affimed Announces Listing Transfer to Nasdaq Capital Markets

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK(R) for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Affimed N.V. Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

Second quarter 2023 earnings released: €0.20 loss per share (vs €0.13 loss in 2Q 2022)

Affimed N.V. to Report Q2, 2023 Results on Aug 10, 2023

New minor risk - Market cap size

Affimed N.V.(NasdaqGM:AFMD) dropped from Russell 2000 Dynamic Index

Affimed Announces Addition of Constanze Ulmer-Eilfort to Its Supervisory Board

Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

First quarter 2023 earnings released: €0.21 loss per share (vs €0.14 loss in 1Q 2022)

Affimed N.V., Annual General Meeting, Jun 21, 2023

Affimed N.V. to Report Q1, 2023 Results on May 23, 2023

Affimed N.V. Announces Abstracts at Annual Meeting of European Hematology Association

Full year 2022 earnings released: €0.60 loss per share (vs €0.48 loss in FY 2021)

Affimed N.V. Provides Regulatory Update for AFM13

Affimed N.V. Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

Affimed N.V. Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells

Now 23% undervalued after recent price drop

Third quarter 2022 earnings released: €0.11 loss per share (vs €0.14 loss in 3Q 2021)

Affimed N.V. to Report Q3, 2022 Results on Nov 15, 2022

Affimed N.V. Announces Presentation of Phase 1/2 Data from Afm13 in Combination with Allogeneic NK Cells and Preclinical Afm28 Data At Ash 2022 Annual Meeting

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released: €0.13 loss per share (vs €0.16 loss in 2Q 2021)

Affimed N.V. to Report Q2, 2022 Results on Aug 11, 2022

Affimed N.V. Establishes Scientific Advisory Board

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

First quarter 2022 earnings released: €0.14 loss per share (vs €0.012 profit in 1Q 2021)

Affimed N.V. Announces Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies At the Annual Meeting of the American Society of Clinical Oncology

Affimed N.V. to Report Q1, 2022 Results on Jun 01, 2022

Affimed N.V. Presents Data on Innate Cell Engagers Afm24 and Afm28 at 19th Meeting of the Society for Natural Immunity

Affimed N.V. Announces Data from the Dose Escalation Phase of the Phase 1/2A Study with the company’s Innate Cell Engager

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

Affimed N.V. Presents Findings from the Dose-Escalation Phase of the First-In-Human Study of AFM24 in Patients with EGFR-Positive Solid Tumors

Full year 2021 earnings released: €0.48 loss per share (vs €0.50 loss in FY 2020)

Affimed N.V. Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers After Freezing & Thawing

Affimed N.V. Announces Completion of Enrollment in Redirect, the Registration-Directed Study of Afm13 in PTCL

Affimed N.V. to Discuss Treatment of Cd30-Positive Lymphoma Patients with Cord Blood-Derived Natural Killer Cells Pre-Complexed with Innate Cell Engager AFM13

Affimed N.V. Initiates Patient Recruitment for A Phase 1/2A Trial of Innate Cell Engager Afm24 in Combination with Roche’S Anti-Pd-L1 Checkpoint Inhibitor Atezolizumab

Affimed Announces Interim Clinical Results from the Investigator-Initiated Phase 1-2 Study At the University of Texas MD Anderson Cancer Center

Third quarter 2021 earnings released: €0.14 loss per share (vs €0.069 loss in 3Q 2020)

Second quarter 2021 earnings released: €0.16 loss per share (vs €0.15 loss in 2Q 2020)

First quarter 2021 earnings released: EPS €0.012 (vs €0.11 loss in 1Q 2020)

Affimed N.V. Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of Afm13 in Combination with Natural Killer Cells

Full year 2020 earnings released: €0.50 loss per share (vs €0.50 loss in FY 2019)

Affimed N.V. Announces Continuation of REDIRECT, a Registration-Directed Study of AFM13 in PTCL, After Positive Preplanned Interim Futility Analysis

New 90-day low: €4.00

Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors

Affimed N.V. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Affimed Announces Pipeline and Business Update

New 90-day high: €5.67

Affimed N.V. Announces Publication of Final Study Results of Its Innate Cell Engager Candidate AFM13 in Combination with MSD’s Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) in Blood

New 90-day high: €3.65

Revenue beats expectations

Third quarter 2020 earnings released: €0.069 loss per share

Affimed N.V. Announces Preclinical Data Generated Through Collaboration with the University of Texas MD Anderson Cancer Center and Washington University School of Medicine

Affimed N.V. and Roivant Sciences Enter Licensing and Strategic Collaboration Agreement

Artiva Biotherapeutics, Inc., and Affimed N.V. Announces Platform-To-Platform R&D Collaboration for Targeted Off-The-Shelf NK Cell Therapies

Affimed N.V. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: €2.70

Affimed N.V. Announces Dosing of First Patient in Phase 1 Clinical Trial of Cord Blood-Derived Natural Killer Cells in Combination with the Innate Cell Engager AFM13

Affimed Announces Milestone Payment from Genentech and ROCK(R) Platform Presentation At Innate Killer Summit 2019